MARKET

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.74
-0.49
-4.36%
Opening 11:51 03/05 EST
OPEN
11.22
PREV CLOSE
11.23
HIGH
11.26
LOW
10.51
VOLUME
677.94K
TURNOVER
--
52 WEEK HIGH
19.43
52 WEEK LOW
4.810
MARKET CAP
1.54B
P/E (TTM)
-11.5970
1D
5D
1M
3M
1Y
5Y
--Analyst Actions: Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $29 From $36, Maintains Overweight Rating
MT Newswires · 2d ago
Is Sangamo Therapeutics (SGMO) Stock a Buy For 2021?
Wasatch Ultra Growth Fund recently released its Q4 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 23.2% for the quarter, underperforming its benchmark, the Russell 2,000 Growth Index which returned 29.6% in the sam...
Insider Monkey · 4d ago
Cerebrovascular Disease Market Statistics And Projected Developments (2022-2031) | Johnson and Johnson
Mar 01, 2021 (WiredRelease via Comtex) -- A recent systematic review report on “Cerebrovascular Disease Market Key Factors and Emerging Opportunities with...
marketresearch.biz · 4d ago
Stock Market News for Feb 26, 2021
Zacks.com · 6d ago
Stock Market News for Feb 26, 2021
Zacks.com · 02/26 14:34
Gene editing market size is expected growing at a CAGR of around 15.3% during forecast period 2019 to 2026
Comserve · 02/25 10:15
DJ Sangamo Therapeutics, Inc. CEO Sandy Macrae on Q4 2020 Results -- Earnings Call Transcript >SGMO
Dow Jones · 02/25 04:57
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
Zacks.com · 02/25 00:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SGMO. Analyze the recent business situations of SANGAMO THERAPEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SGMO stock price target is 19.90 with a high estimate of 30.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 342
Institutional Holdings: 84.88M
% Owned: 59.25%
Shares Outstanding: 143.25M
TypeInstitutionsShares
Increased
70
8.28M
New
60
-6.52M
Decreased
68
5.13M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.30%
Pharmaceuticals & Medical Research
-1.18%
Key Executives
President/Chief Executive Officer/Director
Alexander Macrae
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Gary Loeb
Executive Vice President
D. Mark McClung
Chief Financial Officer
Prathyusha Durabaibu
Executive Vice President
R. Andrew Ramelmeier
Senior Vice President
Rob Schott
Chief Scientific Officer
Jason Fontenot
Vice President - Finance
Prathyusha Duraibabu
Director
Kenneth Hillan
Independent Director
Robert Carey
Independent Director
John Markels
Independent Director
James Meyers
Independent Director
H. Stewart Parker
Independent Director
Saira Ramasastry
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
No Data
  • All
  • Financials
  • Insiders
More
About SGMO
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Webull offers kinds of Sangamo Therapeutics Inc stock information, including NASDAQ:SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.